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Abstract
Background: Melanomas within the alimentary tract are usually metastatic in origin. On the other hand, primary
melanomas of the gastrointestinal tract are relatively uncommon. There are several published reports of
melanomas occurring in the esophagus, stomach, small bowel, and anorectum. The occurrence of primary
melanoma of the colon has, however, only been rarely reported. The optimum modus operandi for the
management of primary colonic melanoma remains nebulous due to the limited number of reports in literature.
Methods: A comprehensive search of Medline, Cochrane and Highwire was performed using the following
keywords: ‘melanoma’, ‘malignant melanoma’, ‘primary melanoma’, ‘colon’, ‘gastrointestinal tract’, ‘alimentary tract’,
‘digestive tract’, and ‘large bowel’. All patients with primary melanoma localized to the colon were included in the
review. Patients with metastatic melanomas to the gastrointestinal (GI) tract and primary melanomas localized to
the GI tract in anatomic locations other than colon were excluded.
Results: There have been only 12 reported cases of primary melanoma of the colon to date. The average age
of patients on presentation was 60.4 years without any significant gender predilection. Right colon (33%) and
cecum (33%) were the most common sites for the occurrence of primary colonic melanoma while abdominal
pain (58%) and weight loss (50%) were the most common presenting complaints. Colonoscopy is the most
reliable diagnostic investigation and offers the additional advantage of obtaining tissue for diagnosis. S-100 and
HMB-45 are highly sensitive and specific for the diagnosis of this malignancy. For primary colonic melanomas
that have not metastasized to any distant parts of the body, surgical resection with wide margins appears to be
the treatment of choice. Although the management was individualized in every case, most of the authors
preferred traditional hemicolectomy as the favored surgical approach. Chemotherapeutic agents including
interferons, cytokines, biological agents and radiation therapy for brain metastases have been reported as
adjuvant and palliative options while considering malignant melanomas in general. The average recurrence-free
interval was 2.59 years. Nine of the 12 reports documented follow-up in their patients. Two of these 9 (22.2%)
patients died.
Conclusions: Primary melanoma of the colon is a rare clinical entity. Whenever a seemingly primary melanoma
is detected in an atypical location such as the colon, it is prudent to conduct a thorough clinical investigation
to consider the possibility of metastatic disease. Further studies are needed to document the long term follow-
up, survival advantage and safety of the management approaches employed in patients with primary colonic
melanoma. Based on current data, surgical resection appears to be appropriate management for primary
colonic melanomas; unless the disease has metastasized to distant sites where surgery may have a limited
palliative role.
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Melanomas within the alimentary tract are usually meta-
static in origin, with primary melanomas being relatively
uncommon. The theory of primary melanoma of the
gastrointestinal (GI) tract has been confirmed for lesions
occurring in the esophagus, stomach, small bowel, and
anorectum through several published reports, as these
are the areas where melanocytes normally exist. How-
ever, the occurrence of primary melanoma in the colon
is relatively rare. Nevertheless, such incidence is con-
founded by the embryologic absence of melanocytes in
the large bowel [1]. The optimum modus operandi for
the management of primary colonic melanoma also
remains unclear. In this review, we have evaluated these
cases and presented the collective data along with a
review of the relevant literature with particular reference
to the pathogenesis, diagnosis and management of pri-
mary melanoma of the colon.
Methods
The computerized databases of Medline, Cochrane and
Highwire were searched using the following keywords:
‘melanoma’, ‘malignant melanoma’, ‘primary melanoma’,
‘colon’, ‘gastrointestinal tract’, ‘alimentary tract’, ‘diges-
tive tract’,a n d‘large bowel’. The references for each
article were, in turn, also reviewed in detail for other
reports of primary melanoma of the colon that may not
have been detected during our initial search. All patients
with primary melanoma localized to the colon were
included in this review. Patients with metastatic melano-
mas to the gastrointestinal (GI) tract and primary mela-
nomas localized to the GI tract in anatomic locations
other than the colon were excluded. The details of these
12 cases are summarized in Table 1 [1-12].
Epidemiology
a. Types of melanoma
Worldwide, more than 7,000 people die of malignant mel-
anoma every year [13]. The vast majority of these cases
are cutaneous melanomas. In the remaining cases, ocular
melanomas are the most common type, followed by the
melanomas in leptomeninges, oral cavity, nasal mucosa,
pharynx, esophagus, bronchus, and vaginal or anorectal
mucosa [14]. Overall, only 20% of these non-cutaneous
melanomas originate in the mucosa, accounting for 3-4%
of all melanomas that are diagnosed annually [2].
b. Family history
Generally, a positive family history is an established risk
factor for developing melanomas. In population-based
studies, 1 - 13% of cases have reported melanoma in at
least one first-degree relative [15].
c. Gastrointestinal involvement
Approximately 1-4% of all patients with malignant
melanoma will have clinically apparent GI tract
involvement diagnosed ante-mortem, and as many as
60% of all patients with melanoma are found to have
GI tract metastasis at autopsy [3]. According to a
review performed at Memorial Sloan Kettering Can-
cer Center (MSKCC), the incidence of GI tract
metastases of melanomas was calculated to be as fol-
lows: liver: 68%, small intestine: 58%, colon: 22%, sto-
mach: 20%, duodenum: 12%, rectum: 5%, esophagus
4% and anus 1% [16]. Other studies have validated
these findings [17].
Pathogenesis of primary melanoma of the colon
a. Relation to neural crest cells
Neural crest cells are found extensively in the intestines,
and are believed to have developed from caudal bran-
chial arches during embryogenesis. In vitro, the bowel
has been shown to favor the differentiation of these cells
into mature melanocytes. However, this effect has not
been successfully replicated in vivo which explains the
absence of mature melanocytes in the intestines. In the-
ory, melanomas can only arise at sites that house either
melanocytes or cells that are capable of melanocytic dif-
ferentation. Hence, it is no surprise that these tumors
are predominantly found in the skin. This also explains
why they rarely arise in the colon [18].
b. Model of tumor regression
The presence of potentially metastatic melanomas in the
colon with unknown primaries can be explained by the
model of tumor regression. A variation in immunologic
status, such as infection or pregnancy, can be associated
with spontaneous regression of melanomas in their pri-
mary sites. In a study of 437 cutaneous melanoma cases,
12.3% of all tumors showed at least partial regression
[19]. Histologic findings seen in cases of tumor regres-
sion include dermal lymphocytic infiltration with mela-
nophages, vascular proliferation, absence of malignant
melanoma cells and reparative fibrosis [20].
c. Ectodermal differentiation
However, some colonic melanomas are indeed truly pri-
mary tumors. The probable genesis of such tumors
involves a concept of “ectodermal differentiation” -t h a t
ectodermal cells are capable of differentiation into mul-
tiple cell lines and may variably migrate into the colon
during the embryologic stages to develop into melano-
cytes [7]. The omphalomesenteric duct may provide one
potential route for this transfer of cells [3]. Such a pro-
cess may also drive the melanoblastic cells from the anal
region into the distal colon. Finally, primitive stem cells
localized within the gut wall may also give rise to het-
erotropic melanocytes in the colon [21] and these in
turn can give rise to the primary melanoma of the
colon. However, despite these theories, the true patholo-
gical basis for the occurrence of melanocytes within the
colon remains speculative.
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Whenever a seemingly primary melanoma is detected in
an atypical location such as the colon, it is prudent to
conduct a thorough clinical investigation to consider the
possibility of metastatic disease.
a. History and physical examination
A thorough history and comprehensive physical exami-
nation are primary tools in this regard. Oculocutaneous
melanomas, being the most common primary melano-
mas, should be excluded first as a matter of common
clinical sense. It is possible that a partially regressed
tumor maybe found during this exercise and a high
index of suspicion should be entertained to completely
exclude a malignant lesion. In one study, head and neck
and trunk regions were found to be the favored sites for
primary melanomas in men while in women, primary
melanomas were seen more commonly in the lower
extremity [22]. An examination of all the major lymph
node groups should be undertaken as the presence of
regional lymphadenopathy in a particular area may give
a clue to the site of the primary melanoma if anatomic
knowledge of the usual routes of lymphatic drainage is
applied to the clinical scenario. Also, melanomas can
even arise de novo in lymphatic tissue [23]. Gynecologic
and abdominal examinations (including rectal examina-
tion +/- proctoscopy) should be performed in patients,
especially if they have inguinal lymphadenopathy [24].
Otolaryngologic and ophthamologic examinations
should be done as well; however the recommendations
regarding the performance of these are not uniformly
described. For example, Cormier et al recommend that
ophthalmologic exam be done specifically in patients
with an unknown primary and visceral metastasis to
organs such as the liver [24]. In addition to the com-
plete assessment of the skin, any previous skin biopsies
should be reviewed [24]. In the history, the patient
should be specifically accosted about long standing,
newly experienced or recently modified symptoms in a
systematic manner as well as relevant familial history
about malignancy.
Table 1 Detailed description of the features of 12 reported cases of primary colonic melanoma in medical literature
# Study Year Age/
Sex
Site Tumor
size* (cm)
S-
100
HMB-
45
Melan
A
Management Outcome
1 Serin et al [1] 2010 30, M Cecum 14 + + + Right hemicolectomy and
distal ileectomy
Recurrence free for at least
1 year
2 Poggi et al [2] 2000 79, M Right
colon
8 + + n/a Right hemicolectomy Recurrence free for at least
5 years
3 Avital et al ^^ [3] 2004 41, M Right
colon
6.5 - + + Right hemicolectomy Recurrence free for at least
3 years
4 Venkataraman
et al [4]
2004 59, M Left colon n/a + n/a n/a Disseminated disease, palliative
strategy employed
Not mentioned
5 McNicol et al [5] 2005 84, M Cecum n/a + + n/a Right hemicolectomy Recurrence free for at least
2.5 years
6 Mori et al [6] 2006 88, F Left colon 5 + + + Partial colectomy and regional
lymphadenectomy
Recurrence free for at least
3 years
7 Takahashi-Monroy
et al ^^ [7]
2006 51, F Cecum 4.2 n/a + + Right hemicolectomy and
resection of terminal ileum
Recurrence free for at least
1 year 8 months
8 Mandot et al [8] 2006 62, F Right
colon
n/a + - n/a Brain metastases found at the
time of diagnosis; managed
with steroids, temozolamide
and radiation therapy
Expired within three
months from the time of
diagnosis; cause of death
pyogenic meningitis
9 De Palma et al [9] 2006 56, F Right
colon
n/a + + n/a Right hemicolectomy Recurrence free for at least
2 years
10 Tak et al ^ [10] 2006 72, M Transverse
colon
n/a + + n/a Patient refused any
intervention
Died in 8 weeks from the
time of initial presentation
11 Kenney et al [11] 2007 64,M Transverse
colon
5.5 + - + Left hemicolectomy &
appendectomy
Unremarkable follow up;
recurrence free duration
not mentioned
12 Sashiyama et al
^ [12]
2010 39, F Cecum 2 n/a + n/a Laparoscopic ileocecal
resection
Follow-up not mentioned
n/a = not applicable or information not available.
*greatest dimension of the resected tumor mass (only applicable to cases where surgical intervention was performed).
^ neoplams that were found to be amelanotic on gross appearance.
^^ patient had obstruction secondary to intussusception.
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Baseline laboratory investigations in such patients
should include basic hematological parameters, chest
x-ray and ultrasound of the abdomen. Bone scan, mag-
netic resonance imaging (MRI) or computed tomogra-
phy (CT) scan of the head and either whole body CT
maybe also done [24,25]; however, we feel that the per-
formance of these particular investigations should be
dictated by the presentation profile of the patient and
the investigative discernment of the physician.
c. Role of follow-up surveillance
An additional point to consider is the role of surveil-
lance in the follow-up of these patients as an unknown
primary, although obscure at first, has been reported to
manifest clinically later on [26].
Clinical parameters
a. Age
The average age of patients on presentation in our
review was calculated to be 60.4 years. This finding was
identical to that found in a review of 24 patients of
metastatic colonic melanoma [17].
b. Gender
We did not find any significant gender predilection with
7 patients being male and 5 being female (male
to female ratio of 1.4:1). For comparison, the male
to female ratio in patients with metastatic melanoma to
the colon has been reported as 1.5:1 [17].
c. Sites of involvement
Right colon and cecum were found to be the most com-
mon sites for the occurrence of primary colonic melano-
mas as depicted in Figure 1. This was slightly different
from the data on metastatic colonic melanomas, where
ascending colon and descending colon were reported as
the predominant sites involved [17]. Figure 1 shows a
comparison of the sites involved in primary and meta-
static colonic melanoma.
d. Signs and symptoms
In general, metastatic melanoma should be suspected in
any patient with a history of melanoma who develops
abdominal pain, nausea, vomiting, distension, diarrhea,
melena or anemia [10]. In a study of 24 cases of meta-
static colonic melanomas at MSKCC, bleeding (50%)
was found to be the most common presenting com-
plaint, followed by obstruction (20%), abdominal pain
(20%) and weight loss (16%) [17]. Figure 2 shows a com-
parison of the signs and symptoms seen in primary and
metastatic colonic melanoma. Abdominal pain (58%)
and weight loss (50%) were the chief presenting com-
plaints of the primary colonic melanoma cases in our
review. In contrast, these two complaints were relatively
less common in reported cases of metastatic disease
[17]. This could be explained by the fact that patients
with a history of previously diagnosed melanoma at any
location are less likely to present with GI symptoms at
the time of diagnosis of colonic melanoma. In addition,
Figure 1 Comparison of anatomic distribution in primary and metastatic melanoma of colon.
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suspicion and a lower threshold for conducting investi-
gative and confirmatory testing.
Diagnosis
The diagnostic trajectory of primary colonic melanomas
maybe more protracted as compared to their metastatic
counterparts owing to the absence of a history of
melanoma.
a. Barium studies
Findings of colonic involvement on barium studies
include multiple submucosal nodules, intussusception,
large ulcerative lesions, and extrinsic masses compres-
sing the colon [27].
b. Colonoscopy
Colonoscopy remains the most reliable diagnostic inves-
tigation with a high sensitivity and specificity, and offers
an additional value of obtaining tissue for diagnosis [17].
In our review, colonoscopy alone was performed in
5 patients for the diagnosis of disease [6,9,12]. Two
patients presented with intestinal obstruction secondary
to intussusception, so computed tomography (CT) scan
alone was performed in them [3,10]. Of the remaining
5 patients, 2 were evaluated with CT scan followed by
colonoscopy [4,8] while one each was assessed through
CT scan and Barium Enema [5], CT scan and ultra-
sound of the abdomen [1], and CT scan alone [2]. In
patients in whom colonoscopy was not performed, the
biopsy specimens required for the tissue diagnosis of
melanoma were collected during the surgical procedure.
In our review, the average size of resected neoplasms
was found to be 5.97 cm in the greatest dimension.
c. Histopathology and immunohistochemistry
On histopathology, these tumor cells show varying pro-
portions of epitheloid areas and spindle cells. There may
be in situ change in the overlying or adjacent GI epithe-
lium, which is identified histologically by the presence
of atypical melanocytic cells in the epithelial basal layer
and extension in a “pagetoid” fashion into the more
superficial epithelium. This feature is reported in 40%-
100% of all primary GI melanomas [28]. The tumor
cells may either show abundant melanin pigment or
may be completely amelanotic [29]. In our analysis of
primary colonic melanoma, 14% of the cases were found
to be amelanotic, compared to 30% reported in litera-
ture for metastatic melanoma [17].
The use of special immunohistochemical stains may
prove to be a further aid in securing the diagnosis. S-
100 is highly sensitive for diagnosing melanomas, and
our results calculated the sensitivity of this marker to be
90%. HMB-45 on the other hand is very specific for the
detection of this malignancy. This is because it recog-
nizes a premelanosomal glycoprotein related to the
tyrosinase system, and may thus be negative in undiffer-
entiated amelanotic neoplasms [29]. In our review, 100%
of the pathologic specimens tested for HMB-45 were
Figure 2 Comparison of symptoms in patients with primary versus metastatic melanoma of colon.
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tumor diagnosis.
Once the definitive diagnosis of colonic melanoma has
been established, the next question that accosts a clini-
cian is the determination of the primary or metastatic
origin of the neoplasm. Ozdemir et al proposed strict
diagnostic criteria for bronchial melanoma to be classi-
f i e da sap r i m a r yl e s i o n .T h es a m em a yb ea p p l i e dt o
the colonic lesions as well. According to these criteria,
(1) the lesion must be solitary in the surgical specimen
(2) there must be no previously excised skin tumor (3)
no previous ocular tumor (4) morphology must be com-
patible with primary tumor (5) there must be no other
demonstrable melanomas at the time of surgery (6) find-
ings should be confirmed by careful autopsy [30]. Colo-
nic melanomas not fulfilling these criteria should ideally
be termed secondary. In our review, all these criteria
were met for all patients except the sixth criterion, i.e.
confirmation by autopsy, which was not done in any of
our cases.
Differential diagnosis
There are three other entities that have potentially over-
lapping clinical manifestations with colonic melanoma.
They include gastrointestinal stromal tumor (GIST),
clear cell sarcoma of soft parts (CCS), and epithelioid
malignant peripheral nerve sheath tumor [31].
a. Gastrointestinal Stromal Tumor
On endoscopic evaluation, amelanotic GI melanomas
show striking resemblance to GIST [12]. Furthermore,
nearly 55% of melanomas show some staining for
CD117, and conversely 10% of GISTs stain positively for
S100, particularly if there is neural differentiation
[31,32]. However, strong S-100, HMB-45 and melan-A
positivity and negativity for CD117 favors the diagnosis
of melanoma. Colonic GISTs are also uncommon;
representing only 5% of all GISTS [33].
b. Clear Cell Sarcoma
Another differential to be kept in mind is CCS, which
usually harbors the aponeurotic and tendinous areas of
the extremities but can rarely involve the viscera. Like
melanomas, they may also be S-100 positive, but the
histological appearance is usually sufficient to make the
correct diagnosis. CCS appears as a monotonous popu-
lation of round to oval cell with clear cytoplasm and
prominent nucleoli [34]. If there are still doubts, the
(12;22)(q13;q12) translocation can be used to identify
CCS, as demonstrated by Covinsky et al [35].
c. Epithelioid malignant peripheral nerve sheath tumor
Lastly, the epithelioid variant of malignant peripheral
nerve sheath tumor should also be ruled out. These
neoplasms constitute a spindle cell morphologic struc-
ture that is usually monotonous in appearance and may
exhibit S-100 positivity. Areas of necrosis, large vascular
spaces and perivascular concentration of neoplastic cells
are additional findings in favor of epitheloid malignant
peripheral nerve sheath tumor [36].
Management
For primary colonic melanomas that have not metastasized
to any distant parts of the body, surgical resection with
wide margins appears to be the treatment of choice. Che-
motherapeutic agents including interferons, cytokines, bio-
logical agents and radiation therapy for brain metastases
have all been reported as adjuvant and palliative options
while considering malignant melanomas in general [8].
a. Surgical Management
Aggressive surgical resection has traditionally been the
mainstay of treatment for most melanomas that have
not disseminated at the time of diagnosis. This may be
followed by postoperative radiation therapy, chemother-
apy and immunotherapy for any residual disease or
nodal involvement [33,37]. Surgical intervention may
even be warranted for metastatic melanoma of the gut,
since it is not only palliative but also significantly affects
the prognosis [37,38]. As many as 80-90% cases with
non-curable melanoma of the GI tract are likely to
experience symptomatic relief following palliative
surgery [17].
A review of literature on primary melanoma of the
colon did not reveal any specific criteria that authors
have used to assign specific surgical modalities to
patients. Since the patients were managed by different
surgeons, each management approach was individualized
according to the judgment and discernment of the sur-
geon. However, in general, it is easy to appreciate the
general trend that patients with limited, controlled dis-
ease were managed with curative surgical therapy.
Nine out of 12 patients underwent surgical interven-
tion in our review; 7 of these cases had undergone
hemicolectomies, one had undergone partial colectomy
and one case was managed with laparoscopic ileocecal
resection. The extent of the colon removed in the partial
colectomy was not specified by Mori et al [6]. It appears
that traditional hemicolectomy is a favored approach for
primary melanoma of the colon in most instances. For
most patients, the authors did not mention if lymphade-
nectomy was performed. Only 1 report explicitly stated
that lymphadenectomy was carried out [6].
As data on primary colonic melanoma is limited, we
may also consider the results of studies reported in lit-
erature for the metastatic melanoma and attempt a logi-
cal extrapolation of these to primary colonic melanoma.
A study enrolled 24 patients who were diagnosed with
metastatic colonic melanoma at Mayo Clinic Rochester,
Scottsdale and Jacksonville during the interval 1960-
2000 [17]. Seventy five percent of the patients under-
went surgical resection of the tumor with nodal
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survival of 20.4 months while those with negative nodes
lived an average of 34.7 months, with the average being
27.45 months. Overall, the one-year and five-year survi-
val rates were 37% and 21% respectively. Again, the
main limitation is that the authors didn’t calculate indi-
vidual survival rates for the type of surgery performed.
Furthermore, those patients who underwent postopera-
tive chemotherapy had an average survival of 28.3
months compared to 23.3 months for those who did
not, but this difference was not statistically significant
[17]; although a five month survival advantage appears
to be a clinically significant and intuitively reasonable
advantage afforded by postoperative chemotherapy.
Signs of bowel obstruction and perforation were related
to poor survival, with an aver a g el i f ee x p e c t a n c yo fl e s s
than 10 months [17]. None of the patients in our review
had perforation while two of the patients presented with
intestinal obstruction secondary to intusseception. How-
ever, after surgical intervention, both of these patients
remained recurrence free for atleast 20 months and
36 months respectively. Literature on the subject shows
that surgical resection of uncomplicated colonic melano-
mas has led to better outcomes with one patient surviv-
ing to 38 months and the other lost to follow up at
13 months in one series [22].
Of the 12 patients of primary colonic melanomas in
our review, 9 underwent surgical resection of the colo-
nic tumor without any recurrence of the disease in their
respective follow-ups. The average recurrence free inter-
val was 2.59 years in the 12 cases we reviewed. In our
review of existing cases of primary colonic melanoma,
only one patient was managed with laparoscopic surgery
(resection of ileocecum) [12]. This approach needs to be
evaluated in further studies.
b. Chemotherapy
Melanoma is generally believed to be a chemotherapy-
resistant neoplasm. Nevertheless, several chemotherapeu-
tic agents have shown activity ranging from 10% to 25%.
Numerous combination chemotherapy regimens have
also been evaluated, but survival benefit is yet to be
demonstrated [39]. Furthermore, chemotherapy appears
to have a role in only the disseminated cases of primary
malignant melanoma. Dacarbazine has remained the stan-
dard of care for metastatic melanoma over the last four
decades. Temozolamide is another option that was found
to have a response rate comparable to that of dacarbazine
in a randomized control trial. It offers two potential
advantages as it readily crosses the intact blood-brain
barrier and can be used as an oral agent. It was also used
in one of the patients in our review, who presented with
brain metastasis. Other promising options for chemother-
apy in melanoma include cisplatin, carboplatin, nitrosour-
eas, docetaxil and pacetaxil [39].
First described in 1984, Dartmouth regimen (dacarba-
zine/carmustine/cisplatin/tamoxifen) was the first suc-
cessful combination therapy used against melanomas,
with a response rate of 55% observed in a group of
20 patients [40]. Other successful combination regimens
used against melanomas include cisplatin/vinblastine/
dacarbazine [41] and carboplatin/paclitaxel [42].
Prognosis
The prognosis of primary malignant melanoma of the
colon appears to be better than other types of primary
mucosal melanomas. However, both tend to be more
aggressive than their cutaneous counterparts [5].
According to a study on metastatic colonic melanomas,
the overall morality was 47%, with one-year and five-
year survival rates of 60% and 33% [17]. One could
assume the prognosis of the primary colonic melanomas
to be comparatively better. In our review, 9 reports
mentioned a documented follow-up in their patients.
Two of these 9 patients died; hence, the mortality rate
was 22.2%.
Future directions
The past few years have seen numerous advances in our
knowledge regarding the cell signaling pathways that
propel melanoma in humans. The RAS/RAF/MEK/ERK
is one of them, which plays an essential role in mela-
noma cell growth, invasion, and survival. This has been
the focus of avid investigation as a novel therapeutic tar-
get with drugs such as Sorefenib. Such agents have also
been combined with other chemotherapeutic drugs such
as dacarbazine with reasonable results. However, the
major limiting factor is that not all melanoma patients
have the mutation which is essential for Sorafenib to
work [43]. In any case, the emergence of targeted thera-
pies looks very promising for the management of mela-
noma in the years to come.
Conclusion
Primary melanoma of the colon is a rare clinical entity
in medical literature. Whenever a seemingly primary
melanoma is detected in an atypical location such as the
colon, it is prudent to conduct a thorough clinical inves-
tigation to consider the possibility of metastatic disease.
We have presented a review of 12 cases of primary mel-
anoma of the colon that have been reported in the lit-
erature so far in order to gain a better understanding of
the unique features, symptoms, diagnosis and manage-
ment of this rare tumor. However, it is acknowledged
that further studies are needed to document the long
term follow-up, survival advantage and safety profile of
the management approaches employed in patients with
primary colonic melanoma. Based on a synthesis of the
current data, it appears that the management of primary
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resection, unless the disease has metastasized to distant
sites where surgery may have a more limited palliative
role. Targeted biological therapies are a promising pro-
spect in the management of primary colonic melanoma
in the future and should be explored further.
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